JOP20210195A1 - Therapeutic - Google Patents

Therapeutic

Info

Publication number
JOP20210195A1
JOP20210195A1 JOP/2021/0195A JOP20210195A JOP20210195A1 JO P20210195 A1 JOP20210195 A1 JO P20210195A1 JO P20210195 A JOP20210195 A JO P20210195A JO P20210195 A1 JOP20210195 A1 JO P20210195A1
Authority
JO
Jordan
Prior art keywords
therapeutic
diseases
hyperinflammatory
repurposing
mebendazole
Prior art date
Application number
JOP/2021/0195A
Other languages
Arabic (ar)
Inventor
El-Tanani Mohamed
Original Assignee
Al Ahliyya Amman Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Al Ahliyya Amman Univ filed Critical Al Ahliyya Amman Univ
Priority to JOP/2021/0195A priority Critical patent/JOP20210195A1/en
Priority to PCT/JO2022/050011 priority patent/WO2023286104A1/en
Publication of JOP20210195A1 publication Critical patent/JOP20210195A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to repurposing of an existing therapeutic, mebendazole, for use in treating an individual suffering from a condition selected from the group comprising viral infections, autoimmune diseases and diseases arising from hyperinflammatory states.
JOP/2021/0195A 2021-07-15 2021-07-15 Therapeutic JOP20210195A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JOP/2021/0195A JOP20210195A1 (en) 2021-07-15 2021-07-15 Therapeutic
PCT/JO2022/050011 WO2023286104A1 (en) 2021-07-15 2022-07-14 Therapeutic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JOP/2021/0195A JOP20210195A1 (en) 2021-07-15 2021-07-15 Therapeutic

Publications (1)

Publication Number Publication Date
JOP20210195A1 true JOP20210195A1 (en) 2023-01-30

Family

ID=84922582

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0195A JOP20210195A1 (en) 2021-07-15 2021-07-15 Therapeutic

Country Status (2)

Country Link
JO (1) JOP20210195A1 (en)
WO (1) WO2023286104A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1748679A (en) * 2004-09-14 2006-03-22 郑文婕 Mebendazole new form for treating allergic rhinitis
GB201721287D0 (en) * 2017-12-19 2018-01-31 Repos Pharma Ab Treatment for inflammatory disease
CN112138133B (en) * 2020-10-23 2021-10-19 成都中医药大学附属医院 Pharmaceutical composition for treating novel coronavirus pneumonia and preparation method and application thereof

Also Published As

Publication number Publication date
WO2023286104A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
MX2020008581A (en) Camk2d antisense oligonucleotides and uses thereof.
EA202091144A1 (en) GANAXOLONE FOR USE IN THE TREATMENT OF HEREDITARY EPILEPTIC DISEASES
MX2023010751A (en) Novel uses of piperidinyl-indole derivatives.
PH12017502103A1 (en) Methods and kits for treating depression
MX2020009773A (en) Combination therapy.
MX2019012144A (en) Rna for treatment of autoimmune diseases.
WO2018234568A3 (en) Hydroxynorketamine for the use in the treatment of depression
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
MX2022002740A (en) Il-2 conjugates and methods of use to treat autoimmune diseases.
MX2020006973A (en) Alpha-synuclein antisense oligonucleotides and uses thereof.
MX2020007876A (en) Gene therapy for limb-girdle muscular dystrophy type 2c.
MX2020011817A (en) Methods for treating lymphoma.
MX2022014034A (en) Methods of treating covid-19 using bardoxolone methyl or analogs thereof.
MX2022006073A (en) Methods of use of anti-trem2 antibodies.
CL2021002878A1 (en) Treatment and prevention of metabolic diseases
CR20210545A (en) Solid forms of a glyt1 inhibitor
MX2023004170A (en) N-ACETYLGALACTOSAMINE(GAlNAc)-DERIVED COMPOUNDS AND OLIGONUCLEOTIDES.
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
MX2021011596A (en) Compounds and compositions as modulators of tlr signaling.
MX2021005843A (en) Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease.
MX2023005591A (en) Methods of treating diseases and disorders.
MX2022010674A (en) Lypmphocyte population and methods for producing same.
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
JOP20210195A1 (en) Therapeutic